IDEXX Laboratories (IDXX) Earnings Date & Reports

Key Takeaways

• IDEXX Laboratories is scheduled to report its third-quarter 2026 results on Monday, November 2, 2026, before the market opens.
• Wall Street consensus calls for earnings per share (EPS) of approximately $3.70, up about 8.8% from the $3.40 reported a year ago.
• Analysts expect revenue of roughly $1.19 billion, an increase of about 7.7% from the $1.105 billion reported in Q3 2025.
• IDEXX has beaten EPS estimates in each of its last four reported quarters and has not missed in its last eight, giving the stock a strong track record heading into the print.
• Management's full-year 2026 EPS guidance stands at $14.69 to $14.94, a range investors will be watching closely for any update.

Earnings Context and Why It Matters

IDEXX Laboratories is a global leader in veterinary diagnostics, software, and services, and its quarterly results are widely viewed as a barometer for pet healthcare spending. The company generates most of its revenue from its Companion Animal Group (CAG), the segment covering diagnostic testing and instruments for pets. Recent quarters have shown resilience in recurring diagnostic revenue even as U.S. clinical visit volumes have faced pressure, supported by pricing and growing international demand. With shares trading near their one-year low and a stretch of consecutive earnings beats behind it, this report matters because it will test whether IDEXX's growth engine — and its guidance — remains intact heading into 2027.

Earnings Expectations

Heading into the report, consensus estimates point to EPS of about $3.70 on revenue of approximately $1.19 billion. That compares with EPS of $3.40 and revenue of $1.105 billion in the third quarter of 2025, implying solid single-digit growth on both lines.

In its most recent quarter (Q2 2026), IDEXX delivered EPS of $4.27, beating the $3.94 consensus, while revenue rose 9.7% year over year to $1.22 billion. That continued a pattern of consistent upside: the company has exceeded EPS expectations in each of the past four quarters, with a historical average surprise in the mid-single digits. For the full year, management has guided EPS to $14.69–$14.94, while analysts model roughly $14.80 for fiscal 2026.

Beyond the headline figures, investors will focus on CAG diagnostics recurring revenue growth, the pace of instrument placements (including the IDEXX inVue Dx analyzer), international momentum, and margin trends. The company's September acquisition of CoVetAI, a veterinary software and artificial intelligence firm, adds another layer of interest around its technology strategy.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and emerging market opportunities more efficiently than manual screening. As earnings season unfolds, tools like this can help you identify and track stocks such as IDXX alongside broader sector momentum. Explore the AI Screener to refine your watchlist.

Market Reaction and Investor Sentiment

Sentiment heading into the report is mixed. IDEXX shares have outperformed the broader market over the past year but remain near their one-year low, reflecting investor caution around veterinary visit volumes and broader consumer spending on pet care. The analyst community maintains a consensus "Moderate Buy" rating, with average price targets well above the current share price, suggesting a degree of optimism about the long-term story.

Historically, IDEXX's post-earnings moves have been relatively contained, and the stock has shown a pattern of modest drift following releases. Key risk factors this quarter include any softening in U.S. same-store clinical visits, weaker wellness spending, foreign exchange headwinds, and the pace of operating expense growth tied to commercial and innovation investments. A beat-and-raise print — especially on guidance — would likely be the clearest catalyst for a positive reaction.

Forward Outlook and Key Factors to Monitor

The most important signal from this report will be any update to full-year guidance. Management's current EPS range of $14.69–$14.94 anchors expectations, and investors will be watching whether strong instrument placements and recurring diagnostics revenue support a raise or a narrower range.

Beyond the headline numbers, several themes are worth monitoring. First is the trajectory of CAG diagnostics recurring revenue, which has been supported by net price realization and international expansion even as U.S. clinical visit volumes have declined. Second is the adoption of the inVue Dx analyzer and the related pull-through of consumables, which management has highlighted as a growth driver.

Third, the integration of CoVetAI will be worth watching, as it could strengthen IDEXX's software and artificial intelligence capabilities over time. Finally, margin trends, foreign exchange effects, and the balance between growth investment and profitability will shape how investors interpret the quarter. None of this constitutes a forecast of future share-price performance, but these factors will likely determine how the market digests the results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations